Skip to content

Ethanol injection in the treatment of ectopic pregnancy

Comparing the clinical outcomes of ultrasonography-guided direct absolute ethanol injection and laparoscopic surgery in the treatment of ectopic pregnancy: A randomized controlled trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250228064872N1
Enrollment
30
Registered
2025-03-19
Start date
2025-04-21
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ectopic Pregnancy. Ectopic pregnancy, unspecified

Interventions

Intervention 1: Intervention group: Without the need for general anesthesia and, if necessary, under local analgesia, and after confirming blood flow in the gestational sac area during a transvaginal

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Consent to treatment Women aged between 18 to 45 Gestational age between 5 to 10 weeks Hemodynamically stable One of the criteria below that candidates the patient for a laparoscopic surgery in a conventional center: Patient preference, Allergy to MTX, Concurrent intrauterine pregnancy, Lactating, Active Lung disease, Renal disease, Chronic hepatic disorder, Blood dyscrasia, Immune deficiency, Gastric peptic ulcer, Serum ß-hCG level above 3510 mIU/mL, Mass size greater than 3.5 cm, Detectable fetal heartbeat.

Exclusion criteria

Exclusion criteria: Patient's refusal to participate Lost to follow-up Gestational age below 5 or over 10 weeks Suspected fallopian tube rupture, i.e., the presence of hemodynamic instability, heavy bleeding, altered level of consciousness, severe abdominal pain and tenderness

Design outcomes

Primary

MeasureTime frame
Maternal serum ß-hCG level. Timepoint: Two hours after the injection, the patients' serum ß-hCG levels are checked. If a 20% decrease compared to the baseline level is not observed, a second injection is administered following the same protocol. Subsequently, the patients' serum ß-hCG levels are checked on days 1, 4, and 7 after the injection and then weekly until they become negative. Method of measurement: Enzyme immunoassay.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Tarafdari Manshadi

Tehran University of Medical Sciences

azadehmehr@gmail.com+98 21 6119 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026